 BRIDGEWATER, N.J.--BUSINESS WIRE--Amneal Pharmaceuticals, Inc. NYSE: AMRX Amneal or the Company today announced that it has received Abbreviated New Drug Application ANDA approval from the U.S. Food and Drug Administration FDA for the generic version of TobraDex, which adds another complex ophthalmic product to the generics portfolio. Dexamethasone and Tobramycin Ophthalmic Suspension 0.30.1 is the generic version of TobraDex, which is indicated for steroid-responsive inflamm 